0913693 B.C. Company Description
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits.
Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons.
The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration.
It is also involved in the developing DermaPrecise, a dermal injection device. 0913693 B.C.
Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs.
The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025.
0913693 B.C. Ltd. is based in Vancouver, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Andrew Schutte |
Contact Details
Address: 570 Granville Street Vancouver, BC V6C 3P1 Canada | |
| Phone | 604 248 8730 |
| Website | replicel.com |
Stock Details
| Ticker Symbol | REPCF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA9889361007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew Schutte | President, Chief Executive Officer and Director |
| Dr. Kevin John McElwee Ph.D. | Co-Founder and Chief Scientific Officer |
| David Kwok CPA | Chief Financial Officer |
| Ben Austring | Chief Operating Officer |